130636-61-2

Basic information

• Product Name: 4-(4-NITROBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-(4-NITROBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-[(4-NITROPHENYL)METHYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER;BUTTPARK 36\08-67;4-(4-NITROBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER, 95+%;1-Boc-4-(4-nitrobenzyl)piperazine;tert-butyl 4-[(4-nitrophenyl)Methyl]piperazine-1-carboxylate
• CAS NO: 130636-61-2
• Molecular Formula: C₁₆H₂₃N₃O₄
• Molecular Weight: 321.37
• Product Categories: API intermediates
• Mol File: 130636-61-2.mol

Chemical Properties

• Melting Point: 99-100 °C
• Boiling Point: 436.479°C at 760 mmHg
• Flash Point: 217.775°C
• Appearance: /
• Density: 1.209g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C
• PKA: 5.49±0.10(Predicted)
• CAS DataBase Reference: 4-(4-NITROBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-NITROBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(130636-61-2)
• EPA Substance Registry System: 4-(4-NITROBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(130636-61-2)

Safety Data

• Hazardous Substances Data: 130636-61-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
4-(4-NITROBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a research compound for its potential pharmacological properties, contributing to the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(4-NITROBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a key intermediate or building block for the synthesis of more complex organic molecules and pharmaceuticals.
Used in Drug Development:
4-(4-NITROBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is utilized as a candidate in drug development, where its structure and properties are explored for potential therapeutic applications.
Used in Medicinal Chemistry:
In medicinal chemistry, 4-(4-NITROBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is employed as a valuable compound for studying its interactions with biological targets and its potential as a lead compound for the treatment of various diseases.
Note: The specific applications and industries for 4-(4-NITROBENZYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER are not explicitly mentioned in the provided materials. The uses listed above are inferred based on its classification as a chemical compound with potential pharmacological properties and its common use in pharmaceutical research and drug development.

InChI:InChI=1/C16H23N3O4/c1-16(2,3)23-15(20)18-10-8-17(9-11-18)12-13-4-6-14(7-5-13)19(21)22/h4-7H,8-12H2,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 58198-49-5 1-(4-nitrobenzyl)piperazine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 555-16-8 4-nitrobenzaldehdye 
• 100-14-1 4-nitrobenzyl chloride 

Downstream Products

• 304897-49-2 4-(4-tert-butoxycarbonyl-piperazino-methyl)-aniline 
• 422517-67-7 4-piperazinomethyl-nitrobenzene-dihydrochloride 

Relevant articles and documents

Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket

With our previously identified potent NNRTIs 25a and HBS-11c as leads, series of novel thiophene[3,2-d]pyrimidine and thiophene[2,3-d]pyrimidine derivatives were designed via molecular hybridization strategy. All the target compounds were evaluated for their anti-HIV-1 activity and cytotoxicity in MT-4 cells. Compounds 16a1 and 16b1 turned out to be the most potent inhibitors against WT and mutant HIV-1 strains (L100I, K103N, and E138K), with EC50 values ranging from 0.007 μM to 0.043 μM. Gratifyingly, 16b1 exhibited significantly reduced cytotoxicity (CC50 > 217.5 μM) and improved water solubility (S = 49.3 μg/mL at pH 7.0) compared to the lead 25a (S 50 = 2.30 μM). Moreover, molecular docking was also conducted to rationalize the structure-activity relationships of these novel derivatives and to understand their key interactions with the binding pocket.

Sulfonamides incorporating piperazine bioisosteres as potent human carbonic anhydrase I, II, IV and IX inhibitors

Starting from the molecular simplification of (R) 4-(3,4-dibenzylpiperazine-1-carbonyl)benzenesulfonamide 9a, a compound endowed with selectivity for human Carbonic Anhydrase (hCA) IV, a series of piperazines and 4-aminopiperidines carrying a 4-sulfamoylb

Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections

Invasive fungal infections remain a challenge due to lack of effective antifungal agents and serious drug resistance. Discovery of antifungal agents with novel antifungal mechanism is important and urgent. Previously, we designed the first CYP51/HDAC dual

Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties

To yield potent HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with favorable drug-like properties, a series of novel diarylpyrimidine derivatives targeting the tolerant region I of the NNRTI binding pocket were designed, synthesized and b

Triazole CYP51-HDAC double-target antifungal compound as well as preparation method and application thereof

The invention discloses a triazole CYP51-HDAC double-target antifungal compound, which has a structural general formula disclosed in the invention, wherein R is selected from one of the structures disclosed in the invention. According to the triazole CYP5

A class of GPR40 agonist compounds with amide structure, and uses thereof

The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.

Exploiting the Tolerant Region i of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility an

Diarylpyrimidine derivatives (DAPYs) exhibit robust anti-HIV-1 potency, although they have been compromised by E138K variant and severe side-effects and been suffering from poor water solubility. In the present work, hydrophilic morpholine or methylsulfon

Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia

A series of 1-H-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities. A structure-activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is critical for FLT3 and CDK inhibition. Compound 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis. Acute-toxicity studies in mice show that compound 50 (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg). In MV4-11 xenografts in a nude-mouse model, compound 50 can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg). Taken together, these results demonstrate the potential of this unique compound for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.

1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.

NEW FYN KINASE INHIBITORS

The invention relates to new selective FYN kinase inhibitors of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of pain and arthritis, including osteoarthritis and rheumatoid arthritis.